Maryam Jamil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maryam Jamil has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Eun Kyoung Seo
College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea
3 shared publications - Sana Zafar
Pharmacological Sciences Research Lab, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
3 shared publications - Fakhar Ud Din
Nanomedicine Research Group, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
2 shared publications - Kifayat Ullah Shah
Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan
2 shared publications - Muhammad Ibrar Khan
Pharmacological Sciences Research Lab, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
2 shared publications - Parveen Akhtar Buttar
Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
2 shared publications
Latest Publications
- 28 November 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 135
Neuroprotective effect of Continentalic acid by targeting NF-κB/Bcl-2 and oxidative stress signaling in traumatic brain injury in male BALB/c mice
Background Traumatic brain injury (TBI) is characterized as a heterogeneous neurological disorder, which causes a variety of behavioral and functional impairments. Continentalic acid (CA), a diterpenoid acid obtained from Aralia continentalis, possesses anti-inflammatory, anti-apoptotic, and antioxidant properties. Methods In the current study we investigated the neuroprotective properties of CA in an experimental TBI model. An in vivo, weight-drop model of TBI was developed in male BALB/c mice. Following traumatic insult, CA (1, 10, and 50 mg/kg) was administered intraperitoneally for up to 14 days. To assess the protective effects of CA, we performed behavioral tests, spectroscopy, histopathology, and biochemical analyses. Results The results revealed that CA significantly attenuated trauma-evoked neurological functions and improved mechanical as well as periorbital allodynia. CA also restored the structural and molecular composition of traumatized brain tissues. Similarly, CA reversed the histological changes in the cortex region of the traumatized brain sections and improved the neuronal count. CA administration also decreased the level of traumatic microbleeds in the brain. The expression levels of GFAP and Iba1 were significantly reduced by CA. Treatment with CA significantly reduced the expression of TLR-4, NF-κB, and increased the expression of IĸB-α regulatory protein. CA also downregulated the expression of cleaved caspase-3 protein and upregulated the expression of anti-apoptotic Bcl-2 protein and alleviated the DNA damage. CA dramatically improved the levels of GST, GSH, catalase, and SOD while concomitantly reducing NO and LPO levels. The levels of IL-1β and TNF-α were also reduced in the treatment group. Conclusions The results demonstrated that CA (50 mg/kg) exhibited neuroprotective activity in TBI by attenuating inflammation, neuronal apoptosis, and oxidative stress.
- 28 November 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 135
Neuroprotective effect of Continentalic acid by targeting NF-κB/Bcl-2 and oxidative stress signaling in traumatic brain injury in male BALB/c mice
Background Traumatic brain injury (TBI) is characterized as a heterogeneous neurological disorder, which causes a variety of behavioral and functional impairments. Continentalic acid (CA), a diterpenoid acid obtained from Aralia continentalis, possesses anti-inflammatory, anti-apoptotic, and antioxidant properties. Methods In the current study we investigated the neuroprotective properties of CA in an experimental TBI model. An in vivo, weight-drop model of TBI was developed in male BALB/c mice. Following traumatic insult, CA (1, 10, and 50 mg/kg) was administered intraperitoneally for up to 14 days. To assess the protective effects of CA, we performed behavioral tests, spectroscopy, histopathology, and biochemical analyses. Results The results revealed that CA significantly attenuated trauma-evoked neurological functions and improved mechanical as well as periorbital allodynia. CA also restored the structural and molecular composition of traumatized brain tissues. Similarly, CA reversed the histological changes in the cortex region of the traumatized brain sections and improved the neuronal count. CA administration also decreased the level of traumatic microbleeds in the brain. The expression levels of GFAP and Iba1 were significantly reduced by CA. Treatment with CA significantly reduced the expression of TLR-4, NF-κB, and increased the expression of IĸB-α regulatory protein. CA also downregulated the expression of cleaved caspase-3 protein and upregulated the expression of anti-apoptotic Bcl-2 protein and alleviated the DNA damage. CA dramatically improved the levels of GST, GSH, catalase, and SOD while concomitantly reducing NO and LPO levels. The levels of IL-1β and TNF-α were also reduced in the treatment group. Conclusions The results demonstrated that CA (50 mg/kg) exhibited neuroprotective activity in TBI by attenuating inflammation, neuronal apoptosis, and oxidative stress.
- 26 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-15
Saccharomyces boulardii (CNCM I-745) ameliorates Ovalbumin-induced atopic dermatitis by modulating the NF-κB signaling in skin and colon
Atopic dermatitis (AD) is a long-lasting allergic disorder characterized by itching, redness, swelling, dry skin, scaling, inflammation, and tissue damage. The exact cause of AD is still unknown. Steroid medications are frequently utilized in treating AD, but their prolonged use can result in complications. Multiple studies suggest probiotics may regulate the immune system, boost immune functionality, or reduce overactive immune responses. The current study investigated the anti-inflammatory, antioxidant, and immunomodulatory role of Saccharomyces boulardii in Ovalbumin (OVA)-induced AD in a murine model. Balb/c mice were sensitized and challenged with OVA to induce AD-like lesions. S. boulardii 1 × 109 CFU/ml/day/mice was orally administrated either as a pretreatment (administered 7 days before OVA induction and continued till day 28) or concurrent treatment (administered from day 1 and continued till day 28). Dexamethasone (5 mg/kg/day) was used as a standard treatment. S. boulardii alleviated the macroscopic and behavioral changes. Blood inflammatory cells were significantly reduced. Serum IgE levels were decreased. Oxidative stress and histopathological changes (epidermal/dermal thickness, inflammatory cells, collagen deposition) in skin tissue were improved. Similarly, the colon’s antioxidant capacity and histological architecture were also maintained. Expression of proinflammatory cytokines like TNF-⍺ and IL-1β were significantly reduced in skin and colon tissue. The probiotic S. boulardii under study reduced inflammation by downregulating NF-κB signaling in both skin and colon tissue. This study provides a basis for a possible gut-skin axis, which can be targeted to relieve AD symptoms.
- 26 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-15
Saccharomyces boulardii (CNCM I-745) ameliorates Ovalbumin-induced atopic dermatitis by modulating the NF-κB signaling in skin and colon
Atopic dermatitis (AD) is a long-lasting allergic disorder characterized by itching, redness, swelling, dry skin, scaling, inflammation, and tissue damage. The exact cause of AD is still unknown. Steroid medications are frequently utilized in treating AD, but their prolonged use can result in complications. Multiple studies suggest probiotics may regulate the immune system, boost immune functionality, or reduce overactive immune responses. The current study investigated the anti-inflammatory, antioxidant, and immunomodulatory role of Saccharomyces boulardii in Ovalbumin (OVA)-induced AD in a murine model. Balb/c mice were sensitized and challenged with OVA to induce AD-like lesions. S. boulardii 1 × 109 CFU/ml/day/mice was orally administrated either as a pretreatment (administered 7 days before OVA induction and continued till day 28) or concurrent treatment (administered from day 1 and continued till day 28). Dexamethasone (5 mg/kg/day) was used as a standard treatment. S. boulardii alleviated the macroscopic and behavioral changes. Blood inflammatory cells were significantly reduced. Serum IgE levels were decreased. Oxidative stress and histopathological changes (epidermal/dermal thickness, inflammatory cells, collagen deposition) in skin tissue were improved. Similarly, the colon’s antioxidant capacity and histological architecture were also maintained. Expression of proinflammatory cytokines like TNF-⍺ and IL-1β were significantly reduced in skin and colon tissue. The probiotic S. boulardii under study reduced inflammation by downregulating NF-κB signaling in both skin and colon tissue. This study provides a basis for a possible gut-skin axis, which can be targeted to relieve AD symptoms.
- 27 January 2025
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 765, 110317
Suppression of TLR4/NF-κB signaling by kaurenoic acid in a mice model of monosodium urate crystals-induced acute gout
- 27 January 2025
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 765, 110317
Suppression of TLR4/NF-κB signaling by kaurenoic acid in a mice model of monosodium urate crystals-induced acute gout